Evaluation of the effect of sodium-glucose co-transporter 2 inhibition with empagliflozin on morbidity and mortality of patients with chronic heart failure and a reduced ejection fraction: rationale for and design of the EMPEROR-Reduced trial

Citation
Packer M, Butler J, Filippatos GS, et al. Eur J Heart Fail 2019;21:1270–8.